IP Library › Granted Patent US 12,066,429
Granted Patent B2
US 12,066,429 · App. 16/913,376 · Granted Aug 20, 2024

Method for inhibiting the expression of inflammation promoting factors

Inventors: Hiroshi Asahara (Tokyo, JP); Tomoki Chiba (Tokyo, JP); Kentaro Abe (Osaka, JP)
Assignees: National University Corporation Tokyo Medical and Dental University; Nippon Zoki Pharmaceutical Co., Ltd.
G01N33/5023C12N15/1086C12N15/113C12N15/63C12N2310/14C12N2310/18C12N2320/10C12N2320/50G01N2500/02G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,066,429
App. No.
16/913,376
Granted
Aug 20, 2024
Kind
B2
Abstract

Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for the method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.

Claims (2)

1. A method for inhibiting the expression of an inflammation promoting factor comprising administering at least one RBMS2 expression inhibitor and/or at least one RBMS2 function inhibitor to a patient in need of inhibition of the expression of an inflammation promoting factor, wherein the inflammation promoting factor is selected from the group consisting of IL-6, COX-2, IL-8, IL-1B, MMP1, and IL-24; and wherein the at least one RBMS2 expression inhibitor and/or the at least one RBMS2 function inhibitor is selected from the group consisting of a RBMS2-specific siRNA, a RBMS2-specific antisense nucleic acid, and expression vectors thereof.

2. The method according to claim 1 , wherein the patient has at least one disease selected from the group consisting of immune diseases and inflammatory diseases.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: ASAHARA, HIROSHI; CHIBA, TOMOKI; ABE, KENTARO
To: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY; NIPPON ZOKI PHARMACEUTICAL CO., LTD.
Reel/Frame 053658/0145 →
Priority Claims (2)
JP 2016-094931 · May 10, 2016 · national
JP 2016-162120 · Aug 22, 2016 · national
Continuity (2)
Division 16300442
Related Publication 20200386741A1 · Dec 10, 2020